TY - JOUR KW - Science & Technology KW - Life Sciences & Biomedicine KW - Psychiatry KW - Alzheimer's disease KW - dementia KW - biomarkers KW - cerebrospinal fluid KW - consensus KW - MILD COGNITIVE IMPAIRMENT KW - AMYOTROPHIC-LATERAL-SCLEROSIS KW - CREUTZFELDT-JAKOB-DISEASE KW - CEREBRAL AMYLOID ANGIOPATHY KW - FRONTOTEMPORAL LOBAR DEGENERATION KW - PRECLINICAL ALZHEIMERS-DISEASE KW - NEUROFILAMENT LIGHT-CHAIN KW - POSITRON-EMISSION-TOMOGRAPHY KW - GAMMA-SECRETASE INHIBITOR KW - GENOME-WIDE ASSOCIATION PB - TAYLOR & FRANCIS LTD ID - discovery10051422 N2 - In the 12 years since the publication of the first Consensus Paper of the WFSBP on biomarkers of neurodegenerative dementias, enormous advancement has taken place in the field, and the Task Force takes now the opportunity to extend and update the original paper. New concepts of Alzheimer?s disease (AD) and the conceptual interactions between AD and dementia due to AD were developed, resulting in two sets for diagnostic/research criteria. Procedures for pre-analytical sample handling, biobanking, analyses and post-analytical interpretation of the results were intensively studied and optimised. A global quality control project was introduced to evaluate and monitor the inter-centre variability in measurements with the goal of harmonisation of results. Contexts of use and how to approach candidate biomarkers in biological specimens other than cerebrospinal fluid (CSF), e.g. blood, were precisely defined. Important development was achieved in neuroimaging techniques, including studies comparing amyloid-? positron emission tomography results to fluid-based modalities. Similarly, development in research laboratory technologies, such as ultra-sensitive methods, raises our hopes to further improve analytical and diagnostic accuracy of classic and novel candidate biomarkers. Synergistically, advancement in clinical trials of anti-dementia therapies energises and motivates the efforts to find and optimise the most reliable early diagnostic modalities. Finally, the first studies were published addressing the potential of cost-effectiveness of the biomarkers-based diagnosis of neurodegenerative disorders. EP - 328 Y1 - 2018/01/01/ AV - public TI - Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry A1 - Lewczuk, P A1 - Riederer, P A1 - O'Bryant, SE A1 - Verbeek, MM A1 - Dubois, B A1 - Visser, PJ A1 - Jellinger, KA A1 - Engelborghs, S A1 - Ramirez, A A1 - Parnetti, L A1 - Jack, CR A1 - Teunissen, CE A1 - Hampel, H A1 - Lleo, A A1 - Jessen, F A1 - Glodzik, L A1 - de Leon, MJ A1 - Fagan, AM A1 - Luis Molinuevo, J A1 - Jansen, WJ A1 - Winblad, B A1 - Shaw, LM A1 - Andreasson, U A1 - Otto, M A1 - Mollenhauer, B A1 - Wiltfang, J A1 - Turner, MR A1 - Zerr, I A1 - Handels, R A1 - Thompson, AG A1 - Johansson, G A1 - Ermann, N A1 - Trojanowski, JQ A1 - Karaca, I A1 - Wagner, H A1 - Oeckl, P A1 - van Doorn, LVW A1 - Bjerke, M A1 - Kapogiannis, D A1 - Kuiperij, HB A1 - Farotti, L A1 - Li, Y A1 - Gordon, BA A1 - Epelbaum, S A1 - Vos, SJB A1 - Klijn, CJM A1 - Van Nostrand, WE A1 - Minguillon, C A1 - Schmitz, M A1 - Gallo, C A1 - Mato, AL A1 - Thibaut, F A1 - Lista, S A1 - Alcolea, D A1 - Zetterberg, H A1 - Blennow, K A1 - Kornhuber, J JF - The World Journal of Biological Psychiatry SN - 1814-1412 UR - http://dx.doi.org/10.1080/15622975.2017.1375556 N1 - © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/Licenses/bync-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. IS - 4 VL - 19 SP - 244 ER -